Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.45 USD | -25.00% | -.--% | -.--% |
2023 | Evolutionary Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
2023 | Evolutionary Genomics, Inc. Auditor Raises 'Going Concern' Doubt | CI |
Sales 2021 | - | Sales 2022 | - | Capitalization | 4.66M 6.35M |
---|---|---|---|---|---|
Net income 2021 | -2M -2.73M | Net income 2022 | -1M -1.36M | EV / Sales 2021 | - |
Net Debt 2021 | 3.53M 4.81M | Net Debt 2022 | 3.17M 4.32M | EV / Sales 2022 | - |
P/E ratio 2021 |
-1.34
x | P/E ratio 2022 |
-2
x | Employees | 3 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 67.35% |
1 day | -25.00% |
Managers | Title | Age | Since |
---|---|---|---|
Walter Messier
FOU | Founder | 69 | 90-10-31 |
Steve Warnecke
CEO | Chief Executive Officer | 68 | 10-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steve Warnecke
CEO | Chief Executive Officer | 68 | 10-08-31 |
Mark Boggess
BRD | Director/Board Member | 64 | 09-12-31 |
Founder | 74 | 90-10-31 |
1st Jan change | Capi. | |
---|---|---|
-.--% | 2.99M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+44.98% | 40.65B | |
-10.87% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- FNAM Stock